April 10, 2024 Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies The interaction between PD-1 and PD-L1 promotes tumor immune evasion, but immune checkpoint inhibitors can reinvigorate the immune system. However, most pa...
Dive into our cutting-edge research presented at the 2024 AACR Annual Meeting. Our latest poster offers groundbreaking insights into the development of KRAS mutant-specific antibodies, a pivotal step in understanding and combating various cancers. About the AACR Annual Meeting The AACR Annual Meeting ...
Henlius’ phase 3 clinical study of its innovative anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) was published as poster presentation...
在刚落幕的2024 AACR大会上,华东医药靶向 HPK1 PROTAC研究以POSTER展示,接下来更多创新成果即将亮相各大国际会议:口服HPK1小分子抑制剂HDM2004研究入选 2024-CIMT年会POSTER,迈华替尼Ⅲ期关键性临床研究(HDHY-MHTN-III-1907)阳性结果、口服PTPN2小分子抑制剂 HDM2010 研究分别入选2024 ASCO年会POSTER和摘要。 2024年...
◆ 下次会议:2024年第8届CRI-ENCI国际癌症免疫治疗大会(CICON2024) ◆ 会议简介: 2023年第7届CRI-ENCI-AACR国际癌症免疫治疗大会将于2023年9月20日至23日在意大利米兰举行,会议议题涵盖癌症免疫学和免疫治疗的所有研究领域。该会议于2015年启动,由癌症研究所(CRI)、欧洲癌症免疫治疗网络(ENCI)和美国癌症研究协会(...
5. Candidates must either be AACAP members or have a membership application pending (not paid by the award) and agree to submit a poster presentation on his or her research for AACAP's 71st Annual Meeting in Seattle, WA, October 14-19, 2024. Type: Award Value: US$15,000 Country of ...
2024年4月10日,复宏汉霖(2696.HK)宣布,公司首个创新型单抗H药 汉斯状(斯鲁利单抗)一线治疗广泛期小细胞肺癌(ES-SCLC)的国际多中心III期临床试验ASTRUM-005的探索性生物标志物分析数据在2024年美国癌症协会年会(AACR 2024)上以壁报形式展示,该研究的主要研究者为吉林省肿瘤医院程颖教授。